Hunan Baide Biological Products Co., Ltd


The "Internet + drug company" has reached an inflection point. What do you think?

Source: | Author:佚名 | Published time: 2023-09-19 | 743 Views | Share:

It is understood that after the "Internet +" action plan was first proposed in the 2015 government work report, "Internet + traditional industries" has received extensive attention. With the deepening of the “Internet Plus”, in addition to hospitals, doctors, and pharmacies, pharmaceutical companies have more abundant and diverse channels for drug marketing.
In the “Internet + pharmacy” area, at the beginning of 2017, the General Office of the State Council issued the “Several Opinions on Further Reforming and Perfecting the Drug Production, Circulation, and Use Policy”, and called for guiding the “Internet+pharmaceutical Circulation” to develop in a standard manner and supporting the cooperation between drug distribution companies and Internet companies. We will promote the integration of online and offline development and cultivate new business models.
With the "Internet Plus" model, consumers can get feedback on products in the shortest distance and fastest way. And through the traceability of barcodes, it becomes an authoritative and efficient path for consumers to check the authenticity of drugs and understand the knowledge of safe drug use.
The "Guidelines on Actively Promoting "Internet Plus" Actions" and "Notice on Printing and Distributing the "Internet + Human Society" 2020 Action Plan" etc. previously published have also further promoted the development of the "Internet + drug company" model.
"Internet +" should be something pharmaceutical companies are very concerned about and are doing. The terminal value of the “Internet+” era is gradually reflected, and chronic disease management, medical services, and the realization of unmanned wards are closely related to pharmaceutical companies. It can be said that with the promotion of Internet hospitals and Internet health care, the competitiveness of retail sales of pharmaceutical companies has been further enhanced.
At the same time, it can be foreseen that, as society’s increasing emphasis on services, no matter whether it is a doctor’s diagnosis and treatment service, a drug manufacturer or a drug company, it will revisit the market positioning and improve its service quality. The fierce competition in the market won the spotlight and gained more credibility and recognition.